Ignite Creation Date:
2024-05-06 @ 4:06 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04870866
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2022-08-17
First Post:
2021-04-23
Brief Title:
NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia
Sponsor:
University Hospital Akershus
Organization:
University Hospital Akershus
Study Overview
Official Title:
NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2022-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study investigates the effect of dietary supplementation of nicotinamide ribonucleoside NR in children with ataxia telangiectasia AT with main focus on neurological symptoms
Detailed Description:
Ataxia Telangiectasia AT is a genetic disease where patients are born with mutations in the Ataxia- Telangiectasia Mutated ATM gene The gene codes for the ATM kinase which is required for repair of DNA double-stranded breaks and DNA damage response signalling
There is no treatment available for the neurological manifestations of AT
The study investigates the effects of NR 300 mgday during 2 years
There is no treatment available for the neurological manifestations of AT
The study investigates the effects of NR 300 mgday during 2 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None